Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors

Area of Science:

• Oncolytic virology
• Neuro-oncology
• Viral vector engineering

Background:

• High-grade brain tumors are highly lethal, necessitating novel therapeutic strategies.
• Vesicular stomatitis virus (VSV) shows oncolytic potential but causes neurotoxicity.
• Modifying VSV's glycoprotein may mitigate neurotoxicity while preserving oncolytic activity.

Purpose of the Study:

• To engineer and evaluate chimeric oncolytic viruses with reduced neurotoxicity for brain cancer treatment.
• To test if replacing VSV glycoprotein with that of other viruses (Ebola, Lassa, LCMV, rabies, Marburg) eliminates neurotoxicity without compromising oncolytic efficacy.

Main Methods:

• In vitro screening of chimeric viruses for oncolytic activity and cell targeting.
• In vivo testing of selected chimeric viruses in brain tumor models in mice.
• Evaluation of safety, tumor targeting, and efficacy of VSV-LASV-GPC and VSV-EBOV-GP.

Main Results:

• Wild-type VSV was lethal in brain injections; chimeric viruses were tested for safety and efficacy.
• VSV-LASV-GPC demonstrated no adverse effects in the brain and eradicated glioblastoma and melanoma, including metastatic models.
• Intratumoral injection of VSV-LASV-GPC in one tumor led to contralateral tumor targeting and destruction.
• VSV-EBOV-GP was safe but less effective in tumor destruction and survival extension.

Conclusions:

• VSV-LASV-GPC is a safe and highly effective oncolytic chimeric virus for treating brain cancers.
• This virus exhibits broad tropism for multiple cancer types and exquisite tumor specificity.
• VSV-LASV-GPC represents a significant advancement for oncolytic virotherapy in neuro-oncology.